ePrivacy and GPDR Cookie Consent by TermsFeed Generator


Enter one or more items to select relevant trials (e.g. indications…)

Age span:

Study state:

Number of records: 43
Title of the trial Diagnosis
A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Hodgkin Lymphoma
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Indolent Non-Hodgkin Lymphomas
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Non-Hodgkin lymphomas
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Hodgkin Lymphoma
A randomized,double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non-Hodgkin´s lymphoma with untreated follicular non-Hodgkin´s lymphona
A Multicenter, Phase III, open-label, Randomized Study in previously untreated patients with advanced indolent Non-Hodgkins Lymphoma Evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with Rituximab plus chemotherapy followed by GA101 or Rituximab Maintenance therapy in responders indolent Non-Hodgkins lymphoma
An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin Lymphoma Hodgkin lymphoma
A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) Hodgkin lymphoma
First international inter-group study for nodular lymphocyte-predominant Hodgkin´s Lymphoma in children and adolescents Hodgkin´s disease
An open-label, randomized, phase 3 study of Inotuzumab Ozogamicin administered in combination wtih Rituximab compared to defined investigator´s choice therapy in subjects with relapsed or refractory CD22-positive aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy Non-Hodgkin Lymphoma
An open label, multicenter, randomized, phase III study toinvestigate the efficacy and safety of Bendamustine ocmpared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refgractory, indolent Non-Hodgkin´s Lymphoma non-Hodgkin´s lymphoma
A phase 2 proof of concept study to evaluate the efficacy, safety and pharmacokinetics of the HDAC inhibitor 4SC-201 in patients with relapsed or refractory Hodgkin´s lymphoma Hodgkin´s Lymphoma
HD18 for advanced stages in Hodgkins Lymphoma Hodgkins Lymphoma
Multicenter, phase IV, open-label, uncontrolled study to assess the efficacy and safety of a single intravenous dose of palonosetron 0.25 (Aloxi?, Onicit?, Paloxi?) in the prevention of chemotherapy-induced nausea and vomiting in patients with non-hodgking´s lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy Non-Hodgkin´s lymphomas
A phase I/II, open label study of SPC2996 in combination with rituximab for the treatment of relapsed follicular or lymphoplasmacytic non-Hodgkin´s lymphoma. non-Hodgkin´s lymphoma
Prognostic stratified model of immunoRchemotherapy by monoclonal antibody against CD20 antigen )rituximab, Mabthera) in patients younger than 65 year with non-treated CD20 positive B cšell non-Hodgkin´s Lymphoma B-Cell Non-Hodgkin's Lymphoma
A phase III, open-label, multi-centric, single-arm, retreatment study of galiximab in combination with rituximab for subjects with relapsed, follicular non-Hodgkin's lymphoma who previously responded on study 114-NH-301 Follicular non-Hodgkin's lymphoma
First Internatioanl inter-Group Study for classical Hodgkin´s Lymfoma in Childern and adolescent hodgkin's lymfoma in children
A phase II, prospective, non-comparative, multi-center clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte in preventing CNS-relapse in patients with aggressive non-Hodgkin-lymphomas at risk for CNS metastasis Non-Hodgkin-lymphomas
A phase III, randomised, double-blind study of galiximab in combinetion with rituximab compared with rituximab in combination with placebo for the treatment of subjects with relapsed or refractory, follicular non-Hodgkin's lymphoma Non-Hodgkin's lymphoma

‹‹ ‹ 1 2 3 › ››

Pursuant to Section 99 par. 1 indent f) (2) of Act No. 378/2007 Coll., on Pharmaceuticals and on Amendments to Some Related Acts (Act on Pharmaceuticals) as amended, the State Institute for Drug Control publishes information about clinical trials approved in the Czech Republic.
Database included clinical trials approved since the effect of the Act on Pharmaceuticals. Information about clinical trials from the year 2004 – 2007 are being supplemented continuously.
Database, according to Act, doesn´t include bioequivalence trials and clinical trials in phase I (i.e. first-in-man trials, the first stage of testing in human subjects).

Glossary of clinical trials terms:
Sponsor = An individual, company, institution or organization which takes responsibility for the initiation, management and/or financing of a clinical trial.
Study code / Protocol number = trial identifying number for sponsor
EudraCT number = EU trial identifying number
Subject = an individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control; patient or healthy volunteer.
MEK = Ethics Committee for Multicentric Clinical Trials
Double-blind study = A clinical trial design in which neither the participating individuals (subjects) nor the study staff knows which participants are receiving the investigational drug and which are receiving a placebo or another therapy.
Randomized trial = A study in which participants/subjects are randomly (i.e. by chance) assigned to one of two or more treatment arms of a clinical trial.
Multicentric trial = a clinical trial conducted according to a single protocol but at more than one site and therefore, carried out by more than one investigator.
Placebo = an inactive pill, liquid, or powder that has no treatment value.
Last database change: 15. August 2022 at 05:11